Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer

Cancer Cell

Volumn 23, Issue 2, 2013, Pages 159-170

  Weischenfeldt, Joachim ^a   Simon, Ronald ^b   Feuerbach, Lars ^c   Schlangen, Karin ^d   Weichenhan, Dieter ^c   Minner, Sarah ^b   Wuttig, Daniela ^c   Warnatz, Hans Jörg ^d   Stehr, Henning ^d   Rausch, Tobias ^a   Jäger, Natalie ^c   Gu, Lei ^c   Bogatyrova, Olga ^c   Stütz, Adrian M ^a   Claus, Rainer ^c   Eils, Jürgen ^c   Eils, Roland ^c,g   Gerhäuser, Clarissa ^c   Huang, Po Hsien ^c   Hutter, Barbara ^c   Kabbe, Rolf ^c   Lawerenz, Christian ^c   Radomski, Sylwester ^c   Bartholomae, Cynthia C ^c   Fälth, Maria ^c   Gade, Stephan ^c   Schmidt, Manfred ^c   Amschler, Nina ^b   Haß, Thomas ^b   Galal, Rami ^b   Gjoni, Jovisa ^b   Kuner, Ruprecht ^c   Baer, Constance ^c   Masser, Sawinee ^b   von Kalle, Christof ^c   Zichner, Thomas ^a   Benes, Vladimir ^a   Raeder, Benjamin ^a   Mader, Malte ^e   Amstislavskiy, Vyacheslav ^d   Avci, Meryem ^c   Lehrach, Hans ^d   Parkhomchuk, Dmitri ^d   Sultan, Marc ^d   Burkhardt, Lia ^b   Graefen, Markus ^b   Huland, Hartwig ^b   Kluth, Martina ^b   Krohn, Antje ^b   Sirma, Hüseyin ^b   Stumm, Laura ^b   Steurer, Stefan ^b   Grupp, Katharina ^b   Sültmann, Holger ^c   Sauter, Guido ^b   Plass, Christoph ^c   Brors, Benedikt ^c   Yaspo, Marie Laure ^d   Korbel, Jan O ^a,f   Schlomm, Thorsten ^b   more..

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e UNIVERSITY OF HAMBURG   (Germany)

^f EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DNA FRAGMENT; TRANSCRIPTOME;

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; DNA METHYLATION; DNA SEQUENCE; EARLY ONSET PROSTATE CANCER; FUSION GENE; GENE REARRANGEMENT; GENETIC VARIABILITY; GLEASON SCORE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; MALE; MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; SOMATIC CELL GENETICS;

EID: 84873607610     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.01.002     Document Type: Article

References (55)

1. Albertsen P.C., Hanley J.A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
2. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
3. Bastus N.C., Boyd L.K., Mao X., Stankiewicz E., Kudahetti S.C., Oliver R.T.D., Berney D.M., Lu Y.J. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res. 2010, 70:9544-9548.
4. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
5. Brase J.C., Johannes M., Mannsperger H., Fälth M., Metzger J., Kacprzyk L.A., Andrasiuk T., Gade S., Meister M., Sirma H., et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer 2011, 11:507.
6. Bubendorf L., Sauter G., Moch H., Schmid H.P., Gasser T.C., Jordan P., Mihatsch M.J. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J. Pathol. 1996, 178:437-441.
7. Campbell P.J., Stephens P.J., Pleasance E.D., O'Meara S., Li H., Santarius T., Stebbings L.A., Leroy C., Edkins S., Hardy C., et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 2008, 40:722-729.
8. DePristo M.A., Banks E., Poplin R., Garimella K.V., Maguire J.R., Hartl C., Philippakis A.A., del Angel G., Rivas M.A., Hanna M., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011, 43:491-498.
9. Friedländer M.R., Mackowiak S.D., Li N., Chen W., Rajewsky N. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res. 2012, 40:37-52.
10. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 2004, 4:177-183.
11. Gebhard C., Schwarzfischer L., Pham T.H., Schilling E., Klug M., Andreesen R., Rehli M. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res. 2006, 66:6118-6128.
12. Godoy A.S., Sotomayor P.C., Villagran M., Yacoub R., Montecinos V.P., McNerney E.M., Moser M., Foster B.A., Onate S.A. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression. Biochem. Biophys. Res. Commun. 2012, 423:564-570.
13. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
14. Grönberg H. Prostate cancer epidemiology. Lancet 2003, 361:859-864.
15. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., Isaacs W.B., Bova G.S., Liu W., Xu J., et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 2010, 42:668-675.
16. Heidenreich A., Bellmunt J., Bolla M., Joniau S., Mason M., Matveev V., Mottet N., Schmid H.P., van der Kwast T., Wiegel T., Zattoni F. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 2011, 59:61-71. European Association of Urology.
17. Hodgson M.C., Astapova I., Cheng S., Lee L.J., Verhoeven M.C., Choi E., Balk S.P., Hollenberg A.N. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem. 2005, 280:6511-6519.
18. Homer N., Merriman B., Nelson S.F. BFAST: an alignment tool for large scale genome resequencing. PLoS ONE 2009, 4:e7767.
19. Huang S., Gulzar Z.G., Salari K., Lapointe J., Brooks J.D., Pollack J.R. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 2012, 31:4164-4170.
20. Knudsen B.S., Vasioukhin V. Mechanisms of prostate cancer initiation and progression. Adv. Cancer Res. 2010, 109:1-50.
21. Knudson A.G.J. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 1971, 68:820-823.
22. Krohn A., Diedler T., Burkhardt L., Mayer P.S., De Silva C., Meyer-Kornblum M., Kötschau D., Tennstedt P., Huang J., Gerhäuser C., et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am. J. Pathol. 2012, 181:401-412.
23. Kumar A., White T.A., MacKenzie A.P., Clegg N., Lee C., Dumpit R.F., Coleman I., Ng S.B., Salipante S.J., Rieder M.J., et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci. USA. 2011, 108:17087-17092.
24. Lee D.K., Chang C. Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. J. Clin. Endocrinol. Metab. 2003, 88:4043-4054.
25. Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456:66-72.
26. Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009, 25:1754-1760.
27. Li H., Handsaker B., Wysoker A., Fennell T., Ruan J., Homer N., Marth G., Abecasis G., Durbin R. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009, 25:2078-2079. 1000 Genome Project Data Processing Subgroup.
28. Lilja H., Ulmert D., Björk T., Becker C., Serio A.M., Nilsson J.A., Abrahamsson P.A., Vickers A.J., Berglund G. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J. Clin. Oncol. 2007, 25:431-436.
29. Lin C., Yang L., Tanasa B., Hutt K., Ju B.G., Ohgi K., Zhang J., Rose D.W., Fu X.D., Glass C.K., Rosenfeld M.G. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 139:1069-1083.
30. Lin D.W., Porter M., Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer 2009, 115:2863-2871.
31. Liu P.Y., Beilin J., Meier C., Nguyen T.V., Center J.R., Leedman P.J., Seibel M.J., Eisman J.A., Handelsman D.J. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J. Clin. Endocrinol. Metab. 2007, 92:3599-3603.
32. Liu W., Chang B.L., Cramer S., Koty P.P., Li T., Sun J., Turner A.R., Von Kap-Herr C., Bobby P., Rao J., et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin. Cancer Res. 2007, 13:5028-5033.
33. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., Palanisamy N., Chinnaiyan A.M. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009, 326:1230.
34. Minner S., Enodien M., Sirma H., Luebke A.M., Krohn A., Mayer P.S., Simon R., Tennstedt P., Müller J., Scholz L., et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res. 2011, 17:5878-5888.
35. Mohr B.A., Guay A.T., O'Donnell A.B., McKinlay J.B. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin. Endocrinol. (Oxf.) 2005, 62:64-73.
36. Parker C., Muston D., Melia J., Moss S., Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br. J. Cancer 2006, 94:1361-1368.
37. Parkhomchuk D., Borodina T., Amstislavskiy V., Banaru M., Hallen L., Krobitsch S., Lehrach H., Soldatov A. Transcriptome analysis by strand-specific sequencing of complementary DNA. Nucleic Acids Res. 2009, 37:e123.
38. Rausch T., Jones D.T., Zapatka M., Stütz A.M., Zichner T., Weischenfeldt J., Jäger N., Remke M., Shih D., Northcott P.A., et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012, 148:59-71.
39. Rausch T., Zichner T., Schlattl A., Stütz A.M., Benes V., Korbel J.O. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 2012, 28:i333-i339.
40. Reid A.H., Attard G., Brewer D., Miranda S., Riisnaes R., Clark J., Hylands L., Merson S., Vergis R., Jameson C., et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod. Pathol. 2012, 25:902-910.
41. Rubin M.A., Maher C.A., Chinnaiyan A.M. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 2011, 29:3659-3668.
42. Ryan C.J., Elkin E.P., Cowan J., Carroll P.R. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer 2007, 110:81-86.
43. Schlomm T., Iwers L., Kirstein P., Jessen B., Köllermann J., Minner S., Passow-Drolet A., Mirlacher M., Milde-Langosch K., Graefen M., et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod. Pathol. 2008, 21:1371-1378.
44. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
45. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
46. Sultan M., Schulz M.H., Richard H., Magen A., Klingenhoff A., Scherf M., Seifert M., Borodina T., Soldatov A., Parkhomchuk D., et al. A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 2008, 321:956-960.
47. Sun J., Liu W., Adams T.S., Sun J., Li X., Turner A.R., Chang B., Kim J.W., Zheng S.L., Isaacs W.B., et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007, 67:692-700.
48. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
49. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.-W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
50. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
51. Urbanucci A., Sahu B., Seppälä J., Larjo A., Latonen L.M., Waltering K.K., Tammela T.L., Vessella R.L., Lähdesmäki H., Jänne O.A., Visakorpi T. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 2012, 31:2153-2163.
52. Wang J., Mullighan C.G., Easton J., Roberts S., Heatley S.L., Ma J., Rusch M.C., Chen K., Harris C.C., Ding L., et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat. Methods 2011, 8:652-654.
53. Xi R., Hadjipanayis A.G., Luquette L.J., Kim T.M., Lee E., Zhang J., Johnson M.D., Muzny D.M., Wheeler D.A., Gibbs R.A., et al. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc. Natl. Acad. Sci. USA 2011, 108:E1128-E1136.
54. Yang X., Chen M.W., Terry S., Vacherot F., Bemis D.L., Capodice J., Kitajewski J., de la Taille A., Benson M.C., Guo Y., Buttyan R. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 2006, 25:3436-3444.
55. Yu J., Yu J., Mani R.S., Cao Q., Brenner C.J., Cao X., Wang X., Wu L., Li J., Hu M., et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17:443-454.